Anti-pancreatic lipase and anti-adipogenic effects of 5,7,3′,4′,5′-pentamethoxy and 6,2′,4′-trimethoxy flavone - An in vitro study

Ahmad, Bilal; Friar, Emily P.; Taylor, Emerald; Vohra, Muhammad Sufyan; Serpell, Christopher J.; Garrett, Michelle D.; Loo, Jason Siau Ee; Fong, Isabel Lim; Wong, Eng Hwa

doi:10.1016/j.ejphar.2022.175445

Cited by 5 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, in vitro research has con rmed the anti-lipase and anti-fat effects of avones. [55] There is also evidence that avonoids can in uence NF-κB, STAT, COX-2, or NLRP3 in ammasome pathways, thereby restoring immune homeostasis and controlling in ammation in obese individuals. [56] Total avonoid intake has a protective effect on participants with obesity and comorbid diabetes, which aligns with previous research.…”

Section: Discussionmentioning

confidence: 99%

Investigating the Impact of Flavonoid Intake on All-Cause Mortality in Non-Obesity and Obesity with Various Complication: Insights from the National Health and Nutrition Examination Survey 2007-2010 and 2017-2018

Wang,

Xiong,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: It is reported that dietary intake of flavonoid compounds can reduce all-cause mortality and mortality from specific vascular diseases and cancers, but whether dietary intake of flavonoid can affect obesity and obesity-related comorbidities is unknown. Aim: The main objective is to investigate the relationship between flavonoid intake and all-cause mortality in both obese and non-obese individuals, and in combination with diabetes, non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), and chronic kidney disease (CKD). Methods: This study included NHANES participants from 2007-2010 and 2017-2018. Cox regression analysis evaluated the impact of total flavonoid intake on all-cause mortality among participants with varying comorbidity profiles. Subgroup analysis was conducted by separately analyzing the six sub-classes of total flavonoids (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and isoflavones). Sensitivity analysis investigated the impact of total flavonoid intake on all-cause mortality among patients with different comorbidities. Results: During a median follow-up period of 9.92 years (interquartile range (IQR), 5.54-14.29 years), a total of 639 participants died. In comparison to non-obese participants, cox regression analysis revealed a favorable impact of flavonoid intake on all-cause mortality in obese participants with CKD (hazard ratio (HR): 0.22, 95% CI: 0.11-0.44), metabolically healthy obese (MHO) participants (HR: 0.15, 95% CI: 0.07-0.35), obese individuals with diabetes (HR: 0.51, 95% CI: 0.29-0.88), and obese individuals with comorbid CVD (HR: 0.37, 95% CI: 0.17-0.83). Restricted cubic spline (RCS) analysis indicated a non-linear relationship in obese participants, with optimal intake levels ranging from 319.4978 to 448.6907 mg/day. Subgroup analysis revealed varying effects of total flavonoid components in different health conditions, with hazard ratios ranging from 0.06 for higher levels of flavonol to 0.59 for higher levels of anthocyanidins. Conclusions: In comparison to unhealthy individuals without obesity, those with unhealthy obesity who consume flavonoids show a reduced risk of all-cause mortality.

show abstract

Section: Discussionmentioning

confidence: 99%